NCT04556773: A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer

NCT04556773
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: HER2-low
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody, Chemotherapy, Serine-Threonine Kinase Inhibitor, Endocrine (hormone) Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have tumors that are HER2-low (defined as IHC 2+ & ISH-negative or IHC 1+ & ISH-negative or untested); HR+ patients must have been previously treated with at least one line of endocrine therapy (with or without targeted therapy, e.g. CDK4/6, mTOR, PI3-K inhibitors)
Exclusions: Patients with unstable, symptomatic, uncontrolled brain metastases- see trial for details; Patients with prior treatment of an antibody-drug conjugate (ADC) that is comprised of a topoisomerase I inhibitor
https://ClinicalTrials.gov/show/NCT04556773

Comments are closed.

Up ↑